About Atossa Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://atossatherapeutics.com/
Frequently Asked Questions
What is the 52-week range for ATOS?
The 52-week high is $19.35 and the 52-week low is $1.7.
What is the P/E ratio for ATOS?
The P/E ratio data is currently unavailable.
What is the dividend yield for ATOS?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -102.99%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -7412.50%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.94.
Analyst Recommendation Trends
Wall Street analyst consensus for ATOS over the last few months:
Latest ATOS News
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $24 to $25.
Atossa plans shareholder stake in potential PRV proceeds
Shareholders could be set for a cash reward if the biotech wins a voucher upon approval of (Z)-endoxifen.
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today announced that its Board of Directors has approved a plan to issue one contingent value right ("CVR") for each share of Atossa common stock to enable shareholders to share in a portion of any proceeds received from the monetization of Atossa's first qualifying rare pediatric disease priority r
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer, will participate as a panelist at the 13th Aging Research and Drug Discovery Meeting (ARDD 2026), being held October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University in Boston, MA.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-05-12 | Chen Shu-Chih | +10,000 | - | - |
| 2026-05-12 | Remmel H. Lawrence | +10,000 | - | - |
| 2026-05-12 | Finn Jonathan | +10,000 | - | - |
| 2026-05-12 | Galli Stephen J | +10,000 | - | - |
| 2026-05-12 | Cigler Tessa | +10,000 | - | - |
| 2026-05-12 | Steinhart Richard I | +10,000 | - | - |
| 2026-03-27 | QUAY STEVEN C | +65,000 | - | - |
| 2026-03-26 | Daniel Mark James | +63,000 | - | - |
| 2026-01-20 | QUAY STEVEN C | +950,000 | $0.603 | $572,850 |
| 2026-01-20 | QUAY STEVEN C | +331,674 | - | - |
| 2026-01-20 | QUAY STEVEN C | +950,000 | $0.603 | $572,850 |
| 2026-01-20 | QUAY STEVEN C | +325,203 | - | - |
| 2025-10-14 | Daniel Mark James | +578,000 | - | - |